Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

L Klimek1, H Olze2, U Förster-Ruhrmann2

  • 1Zentrum für Rhinologie und Allergologie, Wiesbaden.

Laryngo- Rhino- Otologie
|February 15, 2022
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the interpretation of neck CT/MRI scans by ChatGPT-4V for detecting primary oropharyngeal squamous cell carcinoma: An exploratory study.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

[Use of Omalizumab-biosimilars for CRSwNP in the German Health Care System - a Position Paper of the German Societies for Allergy AeDA and ORL DGHNO-KHC].

Laryngo- rhino- otologie·2026
Same author

Lack of De-Intensification Models for Female Head and Neck Cancer Patients With Favorable Prognosis.

Cancer medicine·2026
Same author

Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR.

Rhinology·2026
Same author

Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR).

Rhinology·2025
Same author

Olfactory implants: international opinion paper on emerging technologies and clinical applications.

Rhinology·2025
Same journal

Guideline-Based Cochlear Implant Care: A Model for Structuring Delegated Technical Aftercare.

Laryngo- rhino- otologie·2026
Same journal

Audiometric evaluation and quality-of-life in OSIA users - a retrospective monocentric study.

Laryngo- rhino- otologie·2026
Same journal

[Diagnosis and treatment of vestibular migraine - recent developments and future treatment strategies].

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
See all related articles
Summary
This summary is machine-generated.

Mepolizumab, an anti-IL5 antibody, offers a new biologic therapy for severe chronic rhinosinusitis with nasal polyps (CRSwNP). It is approved for adult CRSwNP patients inadequately controlled by other treatments.

Area of Science:

  • Immunology
  • Otolaryngology
  • Pharmacology

Background:

  • Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by eosinophilic inflammation.
  • Mepolizumab, an anti-interleukin-5 (IL5) antibody, targets this inflammation.

Purpose of the Study:

  • To analyze the immunology of CRSwNP.
  • To review evidence for mepolizumab in CRSwNP treatment.
  • To provide recommendations for mepolizumab use in Germany.

Main Methods:

  • Literature search of Medline, Pubmed, trial registries, and Cochrane Library.
  • Inclusion of human studies up to December 2021 investigating mepolizumab in CRSwNP.
  • Expert panel review based on international literature and experience.

Related Experiment Videos

Main Results:

  • Recommendations for mepolizumab use in CRSwNP were developed by an expert panel.
  • Evidence supports mepolizumab's role in managing severe CRSwNP.

Conclusions:

  • Understanding CRSwNP immunology enables new biologic therapies.
  • Mepolizumab is approved for severe CRSwNP as add-on therapy.
  • Indicated for adult patients uncontrolled by systemic corticosteroids or surgery.